Rituxan – pharmaceutical daily

October 14, 2019 Off

Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris

Genentech’s study reinforces efficacy and safety of Rituxan for treatment of PV, a rare autoimmune condition characterized by blistering of the skin and mucous membranes, showing that 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with Rituxan compared to 9.5% of patients on mycophenolate mofetil.

September 27, 2019 Off

FDA approves Genentech’s Rituxan (rituximab) in children with two rare blood vessel disorders

By BusinessWire

FDA has approved Genentech’s Rituxan as the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis. Genetech noted that this approval is the first pediatric indication for Rituxan.

February 19, 2019 Off

Roche to get quicker review of its anti cancer Rituxan combination, in August

By Dino Mustafić

Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.